K4 Elite
K4 Elite
Cognitive · 2026-07-28
Comparisons of Semax vs Selank usually treat them as two flavors of the same thing: short Russian peptides, both taken intranasally in the literature, both filed under "nootropics." Structurally and pharmacologically they have almost nothing in common. They come from different parent molecules, engage different signaling systems, and were developed for different research questions. What they genuinely share is an origin story — both came out of the Institute of Molecular Genetics of the Russian Academy of Sciences — and an evidence problem that applies equally to both. This post covers the differences, then the shared problem.
Semax is a heptapeptide (seven amino acids): Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues are the ACTH(4-7) fragment of adrenocorticotropic hormone — the pituitary hormone that drives cortisol release — and the appended Pro-Gly-Pro tail is a stabilizing sequence intended to slow enzymatic breakdown. Critically, Semax retains the behavioral fragment of ACTH without the corticotropic (stress-hormone) activity of the full molecule.
The most-cited mechanistic work concerns BDNF (brain-derived neurotrophic factor — a protein that supports neuron growth and survival) and its receptor TrkB. Dolotov and colleagues reported that a single administration of Semax in rats produced roughly a 1.4-fold increase in hippocampal BDNF protein, a 1.6-fold increase in TrkB tyrosine phosphorylation, and larger increases in the corresponding mRNAs [1]. Follow-up work tracked the temporal dynamics of both NGF and BDNF gene expression across hippocampus, frontal cortex, and retina [2], and separate studies reported that Semax and its Pro-Gly-Pro tail activated transcription of neurotrophins and their receptor genes after experimental cerebral ischemia (laboratory-induced stroke) in rats [3].
The dopaminergic story is more interesting than it is usually reported. Eremin and colleagues found that Semax alone did not alter tissue or extracellular dopamine concentrations in rat striatum. What it did was markedly amplify the effect of D-amphetamine on extracellular dopamine and locomotor activity, alongside gradual increases in 5-HIAA (a serotonin metabolite) [4]. So the accurate framing is modulatory — Semax shifted the response of monoaminergic systems to a stimulus rather than driving release on its own. Anyone describing Semax as a dopamine-releasing agent is overstating that paper. Semax has also been examined for neuroprotection in MPTP-lesioned models of dopaminergic damage [5].
Selank is also a heptapeptide, but built on an entirely different scaffold: Thr-Lys-Pro-Arg-Pro-Gly-Pro. The first four residues are tuftsin, an endogenous immunomodulatory tetrapeptide, again extended with the same Pro-Gly-Pro stabilizing tail. Its research profile is anxiolytic and immunomodulatory rather than neurotrophic.
Two mechanistic threads dominate. First, GABAergic signaling (GABA is the brain's main inhibitory neurotransmitter — the system benzodiazepines act on). Volkova and colleagues profiled rat brain 1 and 3 hours after Selank administration and reported changes in mRNA levels of genes encoding GABA receptor subunits, transporters, and related ion channels [6]; a later study compared GABA, Selank, and olanzapine effects on the same gene set in IMR-32 neuroblastoma cells [7]. Note what this evidence is: transcript-level changes, not demonstrated receptor binding. Selank is not reported to bind GABA-A receptors the way a benzodiazepine does.
Second, enkephalin degradation. Enkephalins are endogenous opioid peptides that are rapidly destroyed by plasma and tissue peptidases. Selank was reported to dose-dependently inhibit enkephalin-degrading enzymes in human serum, and in mice a 100 µg/kg administration produced anxiolytic-like behavior in the open-field test alongside an increased half-life of plasma leu-enkephalin [8]. The proposed mechanism is therefore indirect: prolong the life of endogenous opioid peptides rather than act as an agonist.
Both compounds are registered medicines in Russia, where Semax has been used clinically since the 1990s and Selank is registered in the anxiety indication. Neither has any equivalent status in the United States. Neither is approved by the FDA, and neither is approved by the EMA. Russian registration is not evidence of efficacy by Western regulatory standards, and it does not transfer. In the US both are available only as research materials, which is how Semax and Selank are supplied here.
This is the part that most comparisons omit, and it applies to both peptides equally.
The correct summary is that both peptides have plausible, distinct, published mechanisms and a body of human use in one country — and that this falls well short of the evidence standard applied to approved drugs elsewhere. For deeper single-compound treatments, see our posts on Semax and the BDNF question and on Selank, the anxiolytic peptide that doesn't sedate.
Semax and Selank share a country of origin, a seven-residue length, and a stabilizing tail. Past that they diverge completely: an ACTH-derived BDNF peptide studied in neuroprotection models on one side, a tuftsin-derived GABAergic and enkephalinase-modulating peptide studied in anxiety models on the other. Choose the comparison on mechanism, not on the shared "Russian nootropic" label — and hold both to the same honest standard, which is that the mechanistic work is real and the outcome evidence is thinner than the category's reputation suggests.
Both compounds are supplied strictly for in-vitro and laboratory research use only. Nothing above is medical advice, a dosing recommendation, or a claim of safety or efficacy in humans or animals. These materials are not drugs or supplements and have not been evaluated by the FDA.